Matches in Wikidata for { <http://www.wikidata.org/entity/Q94352282> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- Q94352282 description "wetenschappelijk artikel" @default.
- Q94352282 description "наукова стаття" @default.
- Q94352282 name "AT-18SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])" @default.
- Q94352282 name "AT-18SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])" @default.
- Q94352282 type Item @default.
- Q94352282 label "AT-18SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])" @default.
- Q94352282 label "AT-18SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])" @default.
- Q94352282 prefLabel "AT-18SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])" @default.
- Q94352282 prefLabel "AT-18SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])" @default.
- Q94352282 P1433 Q94352282-372B53C7-B930-4007-8444-43009BF5B9EF @default.
- Q94352282 P1476 Q94352282-CB47F92C-63B4-483E-BD95-8E65AFB220D0 @default.
- Q94352282 P2093 Q94352282-02094A96-B45F-4DC8-9E92-90177FFC3897 @default.
- Q94352282 P2093 Q94352282-224834E2-5574-47D4-9E36-A9A7F85CB495 @default.
- Q94352282 P2093 Q94352282-35A10A9D-5AF3-44A6-9026-1645BD735229 @default.
- Q94352282 P2093 Q94352282-477548EE-BD9E-45B2-A673-3A58E20494AB @default.
- Q94352282 P2093 Q94352282-559E7305-4AF3-4804-88CD-8D3DB3BE2BF2 @default.
- Q94352282 P2093 Q94352282-58882C9B-B56F-4009-BB10-AFC498792E9A @default.
- Q94352282 P2093 Q94352282-72651B5F-B6FA-4B42-9C51-91E2325316AE @default.
- Q94352282 P2093 Q94352282-93FD8B94-547C-4E2F-B912-59D2D6D82793 @default.
- Q94352282 P2093 Q94352282-C0366FCE-A605-4ABE-A717-011F7EFDA184 @default.
- Q94352282 P2093 Q94352282-CCBB9AC4-15CB-4106-B718-24ADE8A86798 @default.
- Q94352282 P2093 Q94352282-D1F06DE0-0427-43CA-89D8-E095C581BC82 @default.
- Q94352282 P304 Q94352282-8874F623-2CA8-4E6F-9F2E-8277FA4BABD2 @default.
- Q94352282 P31 Q94352282-DB0E9B1B-3186-479B-BBCC-BAC8B3C84C81 @default.
- Q94352282 P356 Q94352282-E110723C-E153-44FD-B8BF-47240237D26C @default.
- Q94352282 P433 Q94352282-8AABD917-E59D-4AE8-97D2-668D6BC86BB6 @default.
- Q94352282 P478 Q94352282-3DF65AE0-AD91-4EB6-9357-EEC7217070BB @default.
- Q94352282 P50 Q94352282-737EC4DA-BA36-43E2-8BCF-244AD0EFB61C @default.
- Q94352282 P50 Q94352282-B2B9E341-3647-476E-AB37-DB3EC40BCD78 @default.
- Q94352282 P50 Q94352282-C4CEAEE2-0030-429A-8F5A-3A24907DAFEB @default.
- Q94352282 P577 Q94352282-F1F06D9D-868E-41AE-BA67-52FAAC86D71F @default.
- Q94352282 P921 Q94352282-A4BC48EB-AAA8-483F-8467-71C9CB4AB6D3 @default.
- Q94352282 P921 Q94352282-B82D7887-A40B-4290-8B31-E453D1DE14CF @default.
- Q94352282 P921 Q94352282-EA109D45-AC46-4218-A84E-4FA615477A4E @default.
- Q94352282 P932 Q94352282-A2DCE9BD-F3D9-4B6A-B475-C7DBC2301512 @default.
- Q94352282 P356 NOU237.18 @default.
- Q94352282 P1433 Q15724471 @default.
- Q94352282 P1476 "AT-18SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])" @default.
- Q94352282 P2093 "Antoine F. Carpentier" @default.
- Q94352282 P2093 "Cedric Revil" @default.
- Q94352282 P2093 "Dana Cernea" @default.
- Q94352282 P2093 "Frank Saran" @default.
- Q94352282 P2093 "Khe Hoang-Xuan" @default.
- Q94352282 P2093 "Petr Kavan" @default.
- Q94352282 P2093 "Roger Henriksson" @default.
- Q94352282 P2093 "Ryo Nishikawa" @default.
- Q94352282 P2093 "Tim Cloughesy" @default.
- Q94352282 P2093 "Warren Mason" @default.
- Q94352282 P2093 "Wolfgang Wick" @default.
- Q94352282 P304 "v12-v12" @default.
- Q94352282 P31 Q13442814 @default.
- Q94352282 P356 "10.1093/NEUONC/NOU237.18" @default.
- Q94352282 P433 "Suppl 5" @default.
- Q94352282 P478 "16" @default.
- Q94352282 P50 Q114444382 @default.
- Q94352282 P50 Q51349290 @default.
- Q94352282 P50 Q56384070 @default.
- Q94352282 P577 "2014-11-01T00:00:00Z" @default.
- Q94352282 P921 Q282142 @default.
- Q94352282 P921 Q413299 @default.
- Q94352282 P921 Q425088 @default.
- Q94352282 P932 "4217795" @default.